These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 31377343)

  • 1. External validation of the INCREMENT-CPE mortality score in a carbapenem-resistant Klebsiella pneumoniae bacteraemia cohort: the prognostic significance of colistin resistance.
    Machuca I; Gutiérrez-Gutiérrez B; Rivera-Espinar F; Cano A; Gracia-Ahufinger I; Guzman-Puche J; Marfil-Pérez E; Pérez-Nadales E; Castón JJ; Bonomo RA; Carmeli Y; Paterson D; Pascual Á; Martínez-Martínez L; Rodríguez-Baño J; Torre-Cisneros J;
    Int J Antimicrob Agents; 2019 Oct; 54(4):442-448. PubMed ID: 31377343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical impact of cefepime breakpoint in patients with carbapenem-resistant Klebsiella pneumoniae bacteraemia.
    Lee NY; Lo CL; Chen PL; Syue LS; Li CW; Li MC; Ko WC
    Int J Antimicrob Agents; 2021 Feb; 57(2):106250. PubMed ID: 33264671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mortality Associated with Bacteremia Due to Colistin-Resistant Klebsiella pneumoniae with High-Level Meropenem Resistance: Importance of Combination Therapy without Colistin and Carbapenems.
    Machuca I; Gutiérrez-Gutiérrez B; Gracia-Ahufinger I; Rivera Espinar F; Cano Á; Guzmán-Puche J; Pérez-Nadales E; Natera C; Rodríguez M; León R; Castón JJ; Rodríguez-López F; Rodríguez-Baño J; Torre-Cisneros J
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence and 30-day all-cause mortality of carbapenem-and colistin-resistant bacteraemia caused by Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae: Description of a decade-long trend.
    Balkhair A; Al-Muharrmi Z; Al'Adawi B; Al Busaidi I; Taher HB; Al-Siyabi T; Al Amin M; Hassan KS
    Int J Infect Dis; 2019 Aug; 85():10-15. PubMed ID: 31100418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors and survival of patients infected with carbapenem-resistant Klebsiella pneumoniae in a KPC endemic setting: a case-control and cohort study.
    Cienfuegos-Gallet AV; Ocampo de Los Ríos AM; Sierra Viana P; Ramirez Brinez F; Restrepo Castro C; Roncancio Villamil G; Del Corral Londoño H; Jiménez JN
    BMC Infect Dis; 2019 Oct; 19(1):830. PubMed ID: 31590648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Colistin Resistance in Carbapenem-Resistant Klebsiella pneumoniae: Laboratory Detection and Impact on Mortality.
    Rojas LJ; Salim M; Cober E; Richter SS; Perez F; Salata RA; Kalayjian RC; Watkins RR; Marshall S; Rudin SD; Domitrovic TN; Hujer AM; Hujer KM; Doi Y; Kaye KS; Evans S; Fowler VG; Bonomo RA; van Duin D;
    Clin Infect Dis; 2017 Mar; 64(6):711-718. PubMed ID: 27940944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of combination therapy containing a high-dose carbapenem on mortality in patients with carbapenem-resistant Klebsiella pneumoniae bloodstream infection.
    Giannella M; Trecarichi EM; Giacobbe DR; De Rosa FG; Bassetti M; Bartoloni A; Bartoletti M; Losito AR; Del Bono V; Corcione S; Tedeschi S; Raffaelli F; Saffioti C; Spanu T; Rossolini GM; Marchese A; Ambretti S; Cauda R; Viscoli C; Lewis RE; Viale P; Tumbarello M;
    Int J Antimicrob Agents; 2018 Feb; 51(2):244-248. PubMed ID: 28842283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors and mortality for patients with Bloodstream infections of Klebsiella pneumoniae during 2014-2018: Clinical impact of carbapenem resistance in a large tertiary hospital of China.
    Chang H; Wei J; Zhou W; Yan X; Cao X; Zuo L; Chen S; Yao K; Huang R; Chen Y; Wu C
    J Infect Public Health; 2020 May; 13(5):784-790. PubMed ID: 31843651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequency Determination of Carbapenem-Resistant Klebsiella Pneumoniae (CRKP) Isolated from hospitals in Isfahan of Iran and Evaluation of Synergistic Effect of Colistin and Meropenem on them.
    Gheitani L; Fazeli H; Moghim S; Nasr Isfahani B
    Cell Mol Biol (Noisy-le-grand); 2018 Jan; 64(1):70-74. PubMed ID: 29412797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of carbapenem resistance on the outcome of patients' hospital-acquired bacteraemia caused by Klebsiella pneumoniae.
    Hussein K; Raz-Pasteur A; Finkelstein R; Neuberger A; Shachor-Meyouhas Y; Oren I; Kassis I
    J Hosp Infect; 2013 Apr; 83(4):307-13. PubMed ID: 23313086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment Outcome of Bacteremia Due to Non-Carbapenemase-producing Carbapenem-Resistant Klebsiella pneumoniae Bacteremia: Role of Carbapenem Combination Therapy.
    Lee NY; Tsai CS; Syue LS; Chen PL; Li CW; Li MC; Ko WC
    Clin Ther; 2020 Mar; 42(3):e33-e44. PubMed ID: 32061374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. External validation of INCREMENT-CPE score in a retrospective cohort of carbapenemase-producing Klebsiella pneumoniae bloodstream infections in critically ill patients.
    Papadimitriou-Olivgeris M; Bartzavali C; Georgakopoulou A; Kolonitsiou F; Mplani V; Spiliopoulou I; Christofidou M; Fligou F; Marangos M
    Clin Microbiol Infect; 2021 Jun; 27(6):915.e1-915.e3. PubMed ID: 33444757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of colistin resistance and other predictors on fatality among patients with bloodstream infections due to Klebsiella pneumoniae in an OXA-48 dominant region.
    Menekşe Ş; Çağ Y; Işık ME; Şahin S; Hacıseyitoğlu D; Can F; Ergonul O
    Int J Infect Dis; 2019 Sep; 86():208-211. PubMed ID: 31402295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination Regimens for Treatment of Carbapenem-Resistant Klebsiella pneumoniae Bloodstream Infections.
    Gomez-Simmonds A; Nelson B; Eiras DP; Loo A; Jenkins SG; Whittier S; Calfee DP; Satlin MJ; Kubin CJ; Furuya EY
    Antimicrob Agents Chemother; 2016 Jun; 60(6):3601-7. PubMed ID: 27044555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Colistin resistance increases 28-day mortality in bloodstream infections due to carbapenem-resistant Klebsiella pneumoniae.
    Balkan II; Alkan M; Aygün G; Kuşkucu M; Ankaralı H; Karagöz A; Şen S; Arsu HY; Biçer M; Kaya SY; Karaali R; Mete B; Saltoğlu N; Tabak F
    Eur J Clin Microbiol Infect Dis; 2021 Oct; 40(10):2161-2170. PubMed ID: 33963928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gentamicin therapy for sepsis due to carbapenem-resistant and colistin-resistant Klebsiella pneumoniae.
    Gonzalez-Padilla M; Torre-Cisneros J; Rivera-Espinar F; Pontes-Moreno A; López-Cerero L; Pascual A; Natera C; Rodríguez M; Salcedo I; Rodríguez-López F; Rivero A; Rodríguez-Baño J
    J Antimicrob Chemother; 2015 Mar; 70(3):905-13. PubMed ID: 25344809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidemiology of carbapenem-resistant
    Wang Y; Lei H; Zhang Y; Yang Q; Wang Y; Wang J; Xu C; Yu J; Zhou L; Kang X; Cui L
    Antimicrob Resist Infect Control; 2018; 7():66. PubMed ID: 29942492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A retrospective observational cohort study of the clinical epidemiology of bloodstream infections due to carbapenem-resistant Klebsiella pneumoniae in an OXA-48 endemic setting.
    Aslan AT; Kırbaş E; Sancak B; Tanrıverdi ES; Otlu B; Gürsoy NC; Yılmaz YA; Tozluyurt A; Liste Ü; Bıçakcıgil A; Hazırolan G; Dağ O; Güven GS; Akova M;
    Int J Antimicrob Agents; 2022 Apr; 59(4):106554. PubMed ID: 35176476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High rate of colistin resistance among patients with carbapenem-resistant Klebsiella pneumoniae infection accounts for an excess of mortality.
    Capone A; Giannella M; Fortini D; Giordano A; Meledandri M; Ballardini M; Venditti M; Bordi E; Capozzi D; Balice MP; Tarasi A; Parisi G; Lappa A; Carattoli A; Petrosillo N
    Clin Microbiol Infect; 2013 Jan; 19(1):E23-E30. PubMed ID: 23137235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Colistin resistance in carbapenemase-producing Klebsiella pneumoniae bloodstream isolates: Evolution over 15 years and temporal association with colistin use by time series analysis.
    Tansarli GS; Papaparaskevas J; Balaska M; Samarkos M; Pantazatou A; Markogiannakis A; Mantzourani M; Polonyfi K; Daikos GL
    Int J Antimicrob Agents; 2018 Sep; 52(3):397-403. PubMed ID: 29960007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.